Method for inhibiting renal hypofunction in non-human animal
AssigneeKaneka Corporation
InventorsHirokazu Sakamoto, Hiroetsu Suzuki, Kentaro Katayama, Yuki Tochigi
Life of this patent
Estimating the term…
Abstract
A method for inhibiting renal hypofunction in a non-human animal includes administering cat-derived erythropoietin to the non-human animal. The non-human animal may have renal hypofunction. The non-human animal may have chronic kidney disease and the renal hypofunction may be caused by the chronic kidney disease. The cat-derived erythropoietin may be administered repeatedly at a time interval of 7 to 30 days.
Claims13
A method for inhibiting renal hypofunction in a non-human mammal, the method comprising administering cat-derived erythropoietin to the non-human mammal,
- wherein the administration of the cat-derived erythropoietin inhibits elevation in creatinine concentration in blood and/or elevation in blood urea nitrogen concentration in the non-human mammal,
- wherein the non-human mammal is a non-human mammal having chronic kidney disease without anemia during the administration,
- wherein the cat-derived erythropoietin comprises an amino acid sequence selected from the group consisting of SEQ ID NO:
- 2, SEQ ID NO:
- 3, an active mutant of SEQ ID NO:
- 2, and an active mutant of SEQ ID NO:
- 3,
- wherein the active mutant of SEQ ID NO:
- 2 is an amino acid sequence having 97% or more amino acid identity to SEQ ID NO:
- 2 and is derived from SEQ ID NO:
- 2 by addition, deletion, and/or substitution of one or more amino acids, and exhibits at least 60% of erythropoietin activity of the polypeptide consisting of SEQ ID NO:
- 2,
- wherein the active mutant of SEQ ID NO:
- 3 is an amino acid sequence having 97% or more amino acid identity to SEQ ID NO:
- 3 and is derived from SEQ ID NO:
- 3 by addition, deletion, and/or substitution of one or more amino acids, and exhibits at least 60% of erythropoietin activity of the polypeptide consisting of SEQ ID NO:
- 3,
- wherein the cat-derived erythropoietin is chemically modified with polyethylene glycol (PEG),
- wherein the chronic kidney disease is classified into chronic kidney disease stage I or stage II defined by the International Renal Interest Society at least at the start of the administration,
- wherein a weight-average molecular weight of the PEG is 5 to 40 kDa, and
- wherein administering the cat-derived erythropoietin is performed repeatedly at a time interval of 7 or more days.
A method for inhibiting renal hypofunction in a non-human mammal, the method comprising administering cat-derived erythropoietin to the non-human mammal,
- wherein the administration of the cat-derived erythropoietin inhibits elevation in creatinine concentration in blood and/or elevation in blood urea nitrogen concentration in the non-human mammal,
- wherein the non-human mammal is a non-human mammal having chronic kidney disease without anemia during the administration,
- wherein the cat-derived erythropoietin comprises an amino acid sequence selected from the group consisting of SEQ ID NO:
- 2, SEQ ID NO:
- 3, an active mutant of SEQ ID NO:
- 2 derived from SEQ ID NO:
- 2 by addition, deletion, and/or substitution of a total 1 to 5 amino acids, and an active mutant of SEQ ID NO:
- 3 derived from SEQ ID NO:
- 3 by addition, deletion, and/or substitution of a total 1 to 4 amino acids,
- wherein the cat-derived erythropoietin is chemically modified with polyethylene glycol (PEG),
- wherein the chronic kidney disease is classified into chronic kidney disease stage I or stage II defined by the International Renal Interest Society at least at the start of the administration,
- wherein a weight-average molecular weight of the PEG is 5 to 40 kDa, and
- wherein administering the cat-derived erythropoietin is performed repeatedly at a time interval of 7 or more days.
Dependencies are inferred from the claim text.